TP53 and triple-negative breast carcinoma: To corroborate these findings in a clinically relevant model, we used mice with patient-derived xenografts (PDXs) originating from triple-negative breast cancers (TNBC) with either wt p53 or mutant p53 (Supplementary Fig. 5K).